ATE504586T1 - Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren - Google Patents

Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren

Info

Publication number
ATE504586T1
ATE504586T1 AT07766400T AT07766400T ATE504586T1 AT E504586 T1 ATE504586 T1 AT E504586T1 AT 07766400 T AT07766400 T AT 07766400T AT 07766400 T AT07766400 T AT 07766400T AT E504586 T1 ATE504586 T1 AT E504586T1
Authority
AT
Austria
Prior art keywords
pyrazoloa3
bupyridine
compounds
salt
pde4 inhibitors
Prior art date
Application number
AT07766400T
Other languages
English (en)
Inventor
David George Allen
Nicola Mary Aston
Rodger Phillip Barnett
Reshma Manesh Chudasama
Caroline Jane Day
Christopher David Edlin
Leanda Jane Kindon
Naimisha Trivedi
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0615286A external-priority patent/GB0615286D0/en
Priority claimed from GB0706790A external-priority patent/GB0706790D0/en
Priority claimed from GB0714815A external-priority patent/GB0714815D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE504586T1 publication Critical patent/ATE504586T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07766400T 2006-08-01 2007-07-31 Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren ATE504586T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0615286A GB0615286D0 (en) 2006-08-01 2006-08-01 Compounds
GB0706790A GB0706790D0 (en) 2007-04-05 2007-04-05 Compounds
GB0714815A GB0714815D0 (en) 2007-07-30 2007-07-30 Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
PCT/GB2007/002908 WO2008015416A1 (en) 2006-08-01 2007-07-31 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors

Publications (1)

Publication Number Publication Date
ATE504586T1 true ATE504586T1 (de) 2011-04-15

Family

ID=38996907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07766400T ATE504586T1 (de) 2006-08-01 2007-07-31 Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren

Country Status (17)

Country Link
US (3) US20090325952A1 (de)
EP (1) EP2046787B1 (de)
JP (1) JP2009545579A (de)
AT (1) ATE504586T1 (de)
AU (1) AU2007280214A1 (de)
CA (1) CA2659539A1 (de)
CL (1) CL2007002349A1 (de)
CY (1) CY1111625T1 (de)
DE (1) DE602007013762D1 (de)
DK (1) DK2046787T3 (de)
HR (1) HRP20110434T1 (de)
NZ (1) NZ574533A (de)
PL (1) PL2046787T3 (de)
PT (1) PT2046787E (de)
SI (1) SI2046787T1 (de)
TW (1) TW200840818A (de)
WO (2) WO2008015416A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2046787T3 (pl) * 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
TW201040130A (en) * 2009-04-17 2010-11-16 Merz Pharma Gmbh & Co Kgaa Synthesis of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
EP2605773A1 (de) * 2010-08-19 2013-06-26 Blanchette Rockefeller Neurosciences, Institute Behandlung von kognitiven störungen im zusammenhang mit abnormalen dendritischen spikes anhand von pkc-aktivatoren
EP2628730B1 (de) * 2012-02-16 2017-12-06 Noxell Corporation Mehrstufige eintopfsynthese von salzen des 5-amino-4-nitroso-1-alkyl-1h-pyrazols
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
DE102015000626A1 (de) * 2015-01-22 2016-07-28 Kibion Gmbh Verfahren zum Nachweis von Helicobacter Pylori
CN111732543A (zh) * 2020-08-14 2020-10-02 浙江鼎龙科技有限公司 一种4,5-二氨基-1-(2-羟乙基)吡唑硫酸盐的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200123A (en) 1962-01-26 1965-08-10 Richardson Merreil Inc Imidazoquinolines
JPS4824396B1 (de) 1970-09-09 1973-07-20
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
DE3927761C2 (de) 1989-08-23 1997-11-27 Huels Chemische Werke Ag Verfahren zur Herstellung von Alkoxyalkylidenmalonsäureestern
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
EP0752853B1 (de) 1993-03-10 2005-09-21 Smithkline Beecham Corporation Phosphodiesterase des menschlichen gehirns
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
DE69529101T2 (de) 1994-06-15 2003-11-13 Wellcome Found Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
HUP9902166A3 (en) 1996-06-17 2001-01-29 Smithkline Beecham Plc Substituted benzamide derivatives having anticonvulsant activity, preparation and use thereof, pharmaceutical compositions containing these compounds
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
CA2284218A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsants
AUPO622597A0 (en) 1997-04-15 1997-05-08 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
JPH11174621A (ja) 1997-10-08 1999-07-02 Fuji Photo Film Co Ltd 熱現像写真感光材料
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
ATE363892T1 (de) 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
AU778393B2 (en) 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
EP1218336A2 (de) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Antagonisten des melanin-konzentrierenden hormons
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
EP1301484A2 (de) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin-rezeptor-liganden
SI1775305T1 (sl) 2000-08-05 2015-01-30 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
KR20090057477A (ko) 2001-09-14 2009-06-05 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
GB0208608D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ グループ リミテッド フェネタノールアミン誘導体
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP2006503108A (ja) 2002-09-16 2006-01-26 グラクソ グループ リミテッド ピラゾロ[3,4−b]ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用
EP1554264B1 (de) 2002-10-22 2007-08-08 Glaxo Group Limited Medizinisch verwendbare arylethanolamin verbindungen
EP1556342B1 (de) 2002-10-28 2008-03-26 Glaxo Group Limited Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
WO2005037280A1 (en) 2003-10-14 2005-04-28 Glaxo Group Limited Muscarinic acetycholine receptor antagonists
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
AU2004299277A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
US20080275078A1 (en) 2004-03-16 2008-11-06 Glaxo Group Limited Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
US20090131431A1 (en) 2005-09-29 2009-05-21 Christopher David Edlin Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
PL2046787T3 (pl) 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4

Also Published As

Publication number Publication date
JP2009545579A (ja) 2009-12-24
WO2008015437A1 (en) 2008-02-07
DK2046787T3 (da) 2011-07-18
HRP20110434T1 (hr) 2011-08-31
US20090325952A1 (en) 2009-12-31
CA2659539A1 (en) 2008-02-07
EP2046787B1 (de) 2011-04-06
PT2046787E (pt) 2011-06-15
CY1111625T1 (el) 2015-10-07
CL2007002349A1 (es) 2008-10-10
TW200840818A (en) 2008-10-16
US8003663B2 (en) 2011-08-23
HK1127603A1 (en) 2009-10-02
DE602007013762D1 (de) 2011-05-19
SI2046787T1 (sl) 2011-07-29
NZ574533A (en) 2011-05-27
EP2046787A1 (de) 2009-04-15
AU2007280214A1 (en) 2008-02-07
WO2008015416A1 (en) 2008-02-07
PL2046787T3 (pl) 2011-10-31
US20080058369A1 (en) 2008-03-06
US20090318494A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
ATE504586T1 (de) Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren
TNSN08104A1 (en) Pyrimidine amide compounds as pgds inhibitors
EA200700219A1 (ru) ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 МАР КИНАЗЫ
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
DE60329193D1 (de) Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
NO20063340L (no) Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer
PT1252157E (pt) Carboxamidas de pirimidina uteis como inibidores de isozimas pde4
NO20084005L (no) Aminderivater
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
SG179199A1 (en) Phenyloxadiazole derivatives as pgds inhibitors
JP2011519845A5 (de)
ATE469159T1 (de) Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten
TW200610529A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
IL194392A0 (en) Piperidine derivatives useful as serotonin transporter inhibitors and neurokinin-1 receptor antagonists
DE602006016244D1 (de) Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
PE20081835A1 (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA Y SU USO COMO INHIBIDORES DE LA PDE4
MY135776A (en) PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
TH104555A (th) สารประกอบไพราโซโล[3,4-b]ไพริดีน และการใช้ของมันเป็นตัวยับยั้ง PDE4
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
TH87151A (th) สารประกอบเคมี
TH104555B (th) สารประกอบไพราโซล[3,4-b]ไพริดีน และการใช้ของมันเป็นตัวยับยั้ง PDE4
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer
TH105528B (th) สารประกอบไพริมิดีน เอไมด์ ที่เป็นสารยับยั้งพรอสตาแกลนดิน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2046787

Country of ref document: EP